Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, and heart disease. Patient-specific cells provide the safest, most effective cures for these indications. However, current autologous processes are not scalable due to extensive manual handling, high variability, and expensive facility overhead.
Nabiha Saklayen, CEO and co-founder of Cellino and the current Tory Burch Foundation Fellow in Genomics at the IGI, discusses her work on creating personalized, autologous cell therapies accessible for patients. Cellino’s vision is to make personalized regenerative medicines viable at a large scale for the first time. Cellino’s platform combines label-free imaging and high-speed laser editing with machine learning to automate cell reprogramming, expansion, and differentiation in a closed cassette format, enabling thousands of patient samples to be processed in parallel in a single facility.
Nabiha Saklayen — Nabiha Saklayen is CEO and co-founder of Cellino, a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies. She is also the inaugural Tory Burch Foundation Fellow in Genomics at the IGI. Cellino’s proprietary technology makes personalized stem cell-derived therapies scalable for the first time. Nabiha has published several peer-reviewed articles in the field of pulsed-laser delivery to cells. Nabiha was selected as a Pioneer in MIT Tech Review’s 35 Innovators under 35 list for her patented inventions in cellular laser editing and is on the 2019 Forbes 30 under 30 List for Healthcare. She received her Ph.D. in Physics from Harvard University as a Howard Hughes Medical Institute (HHMI) International Fellow.
Autologous iPSC-Based Therapies at Scale Using an AI-Driven Laser-Editing Platform
IGI Seminar Series | Innovative Genomics Institute | October 12, 2021